Inovio surges on FDA nod for rare throat disease
INO•The FDA granted accelerated approval to Inovio’s Voceryq for recurrent respiratory papillomatosis. The company expects ordering and shipping to begin in about 60 days, with a full commercial launch in Q1 2027.
1. FDA approves Voceryq
The FDA granted accelerated approval to Inovio’s Voceryq to treat recurrent respiratory papillomatosis, a condition that causes airway growths and often requires repeated surgeries. Inovio said Voceryq is the first FDA-approved DNA-based drug and offers adults with the condition a non-surgical treatment option. The company expects the drug to be available for ordering and shipping in about 60 days, with a full commercial launch in Q1 2027.
